Glycemic Effect of Diazoxide in NAFLD

NCT ID: NCT05729282

Last Updated: 2026-01-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-01
• Study Completion Date: 2025-09-10

Brief Summary

The goal of this clinical trial is to compare a two-week course of diazoxide (at two different doses) and placebo in people with overweight/obesity and insulin resistance (IR) with, or at high risk for, non-alcoholic fatty liver disease (NAFLD). The main questions it aims to answer are how mitigation of compensatory hyperinsulinemia with diazoxide affects parameters of glucose and lipid metabolism (how people with IR and NAFLD respond to lowering high insulin levels so that the investigators can see what happens to how the liver handles fat and sugar).

Participants will:

• Take 27 doses of diazoxide (at 1 mg per kg of body weight per dose [mpk] or 2 mpk) or of placebo, over 14 days
• Take 32 doses of heavy (deuterated) water (50 mL each) over 14 days
• Have blood drawn and saliva collected after an overnight fast on four mornings over the two-week study period
• Consume their total calculated daily caloric needs as divided into three meals per day
• Wear a continuous glucose monitor for the two-week study period

Researchers will compare fasting blood tests at intervals during the study period in participants randomized (like the flip of a coin) to diazoxide 1 mpk, diazoxide 2 mpk, or placebo, to see how the drug treatment affects plasma glucose, serum insulin, and serum lipid parameters (triglycerides, free fatty acids, and apolipoprotein B). They will also consume heavy (deuterated) water to assess de novo lipogenesis (building of new fatty acids by the liver).

Detailed Description

Non-alcoholic fatty liver disease (NAFLD) is an under-appreciated complication of lipid dysmetabolism in type 2 diabetes (T2DM). Although it appears that insulin resistance (IR) is a mechanism common to both, the pathophysiology of its connection to unhealthy fat accumulation in the liver remains unclear. The investigators propose that the hyperinsulinemia that accompanies IR drives the excess hepatic de novo lipogenesis (DNL) that characterizes IR-associated NAFLD (IR-NAFLD). As such, despite its potential impact on glucose tolerance, lowering insulin levels might attenuate the pro-steatotic drive in patients with IR. The investigators' long-term objective, therefore, is to blunt endogenous insulin secretion using the insulin anti-secretagogue diazoxide in order to assess the impact on DNL. However, in order to optimize diazoxide treatment conditions, the investigators must first perform a pilot & feasibility study.

This is a single-center, randomized, double blinded, placebo-controlled clinical trial to provide pilot and feasibility data on the use of diazoxide oral suspension to ameliorate hyperinsulinemia in participants with overweight/obesity and insulin resistance (prediabetic state or elevated Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) score, + fasting hyperinsulinemia) who are diagnosed with, or clinically judged to be at high risk of, NAFLD. Participants will be randomized to one of three parallel arms: placebo, diazoxide at 1 mg per kg of body weight (mpk) per dose, or diazoxide at 2 mpk per dose, for a total of 27 doses over 14 days. They will also consume heavy (deuterated) water for a total of 32 doses of 50 ml over 14 days to measure de novo lipogenesis, an exploratory endpoint. They will present for outpatient blood draws and saliva collections after an overnight fast at four time points during the study course. Additionally, participants will follow a weight-maintaining diet and wear a professional continuous glucose monitor (CGM) throughout.

Conditions

Hyperinsulinemia; Insulin Resistance; Non-Alcoholic Fatty Liver Disease; Prediabetic State

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

Placebo

Participants will ingest a placebo solution (27 doses over 14 days) formulated to approximate the taste of diazoxide oral suspension. Blinding will occur by completely covering single-dose oral syringes with labels.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Flavor-approximate placebo consisting of peppermint extract in diet tonic water, thickened with xanthan gum, provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).

FreeStyle Libre Pro

Intervention Type: DEVICE

All participants will wear a FreeStyle Libre Pro continuous glucose monitor (CGM) to track glycemic trends in response to study treatments. Investigators and participants will be blinded to CGM readings until after each participant has completed the trial.

Deuterated water (2H2O/D2O)

Intervention Type: DRUG

All participants will consume 32 aliquots of deuterated water (2H2O/D2O) 50 mL over 14 days to assess hepatic de novo lipogenesis. Tracer enrichment will be determined in blood and saliva.

Diazoxide oral suspension, 1 mg per kg per dose

Participants will ingest diazoxide oral suspension at 1 mg per kg body weight per dose (27 doses over 14 days). Blinding will occur by completely covering single-dose oral syringes with labels.

Group Type: EXPERIMENTAL

Diazoxide oral suspension, 1 mg per kg per dose

Intervention Type: DRUG

Diazoxide oral suspension provided in label-obscured single-use oral syringes at 1 mg per kg per dose (total of 27 doses over 14 days).

FreeStyle Libre Pro

Intervention Type: DEVICE

All participants will wear a FreeStyle Libre Pro continuous glucose monitor (CGM) to track glycemic trends in response to study treatments. Investigators and participants will be blinded to CGM readings until after each participant has completed the trial.

Deuterated water (2H2O/D2O)

Intervention Type: DRUG

All participants will consume 32 aliquots of deuterated water (2H2O/D2O) 50 mL over 14 days to assess hepatic de novo lipogenesis. Tracer enrichment will be determined in blood and saliva.

Diazoxide oral suspension, 2 mg per kg per dose

Participants will ingest diazoxide oral suspension at 2 mg per kg body weight per dose (27 doses over 14 days). Blinding will occur by completely covering single-dose oral syringes with labels.

Group Type: EXPERIMENTAL

Diazoxide oral suspension, 2 mg per kg per dose

Intervention Type: DRUG

Diazoxide oral suspension provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).

FreeStyle Libre Pro

Intervention Type: DEVICE

All participants will wear a FreeStyle Libre Pro continuous glucose monitor (CGM) to track glycemic trends in response to study treatments. Investigators and participants will be blinded to CGM readings until after each participant has completed the trial.

Deuterated water (2H2O/D2O)

Intervention Type: DRUG

All participants will consume 32 aliquots of deuterated water (2H2O/D2O) 50 mL over 14 days to assess hepatic de novo lipogenesis. Tracer enrichment will be determined in blood and saliva.

Interventions

Diazoxide oral suspension, 1 mg per kg per dose

Diazoxide oral suspension provided in label-obscured single-use oral syringes at 1 mg per kg per dose (total of 27 doses over 14 days).

Intervention Type: DRUG

Diazoxide oral suspension, 2 mg per kg per dose

Diazoxide oral suspension provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).

Intervention Type: DRUG

Placebo

Flavor-approximate placebo consisting of peppermint extract in diet tonic water, thickened with xanthan gum, provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).

Intervention Type: DRUG

FreeStyle Libre Pro

All participants will wear a FreeStyle Libre Pro continuous glucose monitor (CGM) to track glycemic trends in response to study treatments. Investigators and participants will be blinded to CGM readings until after each participant has completed the trial.

Intervention Type: DEVICE

Deuterated water (2H2O/D2O)

All participants will consume 32 aliquots of deuterated water (2H2O/D2O) 50 mL over 14 days to assess hepatic de novo lipogenesis. Tracer enrichment will be determined in blood and saliva.

Intervention Type: DRUG

Other Intervention Names

Proglycem; Proglycem; Placebo solution; Heavy water

Eligibility Criteria

Inclusion Criteria

1. Adults aged 18-70 years (using highly effective contraception if of childbearing potential)

2. Body mass index of 27-50 kg/m2

3. Able to understand written and spoken English and/or Spanish

4. Able to have pre-randomization screening labs drawn and study protocol initiated within 30 days of informed consent

5. Diagnosed with, or clinically judged to be at high risk for, non-alcoholic fatty liver disease (NAFLD), also known as metabolic-associated fatty liver disease (MAFLD), by hepatologist or other qualified physician

6. Evidence of insulin resistance, represented by any or all of the following criteria:

i. Meeting either of the American Diabetes Association's definitions for prediabetes or IFG on screening labs:

1. Prediabetes: Hemoglobin A1c 5.7-6.4%

2. IFG: plasma glucose of 100-125 mg dL-1 after ≥ 8-h fast

and/or

ii. Homeostasis Model of Insulin Resistance (HOMA-IR) score ≥ 2.73

7. Fasting hyperinsulinemia (fasting insulin level ≥ 13 µIU/mL) on screening labs

8. Written informed consent (in English or Spanish) and any locally required authorization (e.g., Health Insurance Portability and Accountability Act) obtained from the participant prior to performing any protocol-related procedures, including screening evaluations.

iv. Clinical concern for absolute insulin deficiency (e.g., type 1 diabetes, pancreatic disease)

6. Concerns related to lipid metabolism

i. Known diagnoses of familial hypercholesterolemia, familial combined hyperlipidemia, or familial hyperchylomicronemia

ii. Use of certain lipid-lowering drugs within the 90 days prior to screening:

• Statins or PCSK9 inhibitors for secondary prevention or for treatment of familial hypercholesterolemia. Statins or PCSK9 inhibitors for primary prevention of ASCVD are acceptable.
• Fibrates (e.g., fenofibrate, clofibrate, gemfibrozil)
• High-dose niacin (>100 mg daily)

7. Known, documented history (i.e., not to be newly screened/tested for study purposes), at the time of screening, of any of the following medical conditions:

i. Pancreatic pathology, including but not limited to:

• Pancreatic neoplasia, unless appropriately evaluated and considered benign and not producing hormones
• Chronic pancreatitis
• Acute pancreatitis within the previous 5 years
• Autoimmune pancreatitis
• Surgical removal of any portion of the pancreas

ii. Cardiovascular disease (N.B. uncomplicated hypertension is not exclusionary)

• Atherosclerotic cardiovascular disease
• Stable or unstable angina
• Myocardial infarction
• Ischaemic or hemorrhagic stroke, or transient ischaemic attack
• Peripheral arterial disease (claudication)
• Use of dual antiplatelet therapy (aspirin + P2Y12 inhibitor)
• History of percutaneous coronary intervention
• Heart rhythm abnormalities
• Congestive heart failure of any New York Heart Association class
• Symptomatic valvular heart disease (e.g., aortic stenosis)
• Pulmonary hypertension

iii. Chronic kidney disease, Stage 3 or higher (estimated glomerular filtration rate < 60 mL/min/1.73 m2), of any cause

iv. Chronic liver disease other than uncomplicated NAFLD, including but not limited to:

• Advanced liver fibrosis, as determined by non-invasive testing
• Cirrhosis of any etiology
• Autoimmune hepatitis or other rheumatologic disorder affecting the liver
• Biliopathy (e.g., progressive sclerosing cholangitis, primary biliary cholangitis)
• Chronic liver infection (e.g., viral hepatitis, parasitic infestation)
• Hepatocellular carcinoma
• Infiltrative disorders (e.g., sarcoidosis, hemochromatosis, Wilson disease)

v. Gout

vi. Chronic viral illness (N.B. diagnosis based only on medical history; the investigators will not test for any of these viruses at any point in this study)

• Hepatitis B virus (HBV), unless previously successfully eradicated with antiviral drugs that have been discontinued for at least 90 days prior to screening
• Hepatitis C virus (HCV) infection, unless previously successfully eradicated with antiviral drugs that have been discontinued for at least 90 d prior to screening
• Human immunodeficiency virus (HIV) infection

vii. Malabsorptive conditions

• Active inflammatory bowel disease (quiescent and off medication is acceptable)
• Celiac disease (in remission on gluten-free diet is acceptable)
• Surgical removal of a significant length of intestine

viii. Active seizure disorder (including controlled with antiepileptic drugs)

ix. Psychiatric diseases that:

• Are or have been decompensated within 1 year of screening, and/or
• Require use of anti-dopaminergic antipsychotic drugs associated with significant weight gain/metabolic dysfunction (e.g., clozapine, olanzapine), monoamine oxidase inhibitors, tricyclic antidepressants, or lithium

x. Glucose-6-phosphate dehydrogenase (G6PD) deficiency

• Due to presence of quinine in tonic water placebo

xi. Other endocrinopathies:

• Cushing syndrome (okay if considered in remission after treatment, provided that no exogenous corticosteroids are required)
• Adrenal insufficiency
• Primary aldosteronism

xii. Venous thromboembolic disease (deep vein thrombosis or pulmonary embolism) or any required use of therapeutic anticoagulation

xiii. Active malignancy, or hormonally active benign neoplasm, except allowances for:

• Non-melanoma skin cancer
• Differentiated thyroid cancer (AJCC Stage I only)

8. Clinical concern for increased risk of volume overload or hypotension (systolic blood pressure <95 and/or diastolic blood pressure <65 mm Hg), including due to medications and/or heart/liver/kidney problems, as listed above

9. Use of certain medications currently or within 90 d prior to screening:

i. Prescribed medications used for any of the indications in the preceding list of excluded conditions, or their use within 90 d prior to screening, except allowances for:

• Statins for primary prevention of cardiovascular disease
• Use of drugs prescribed for indications other than the exclusionary diagnoses/purposes listed above (e.g., non-hydantoin antiepileptic drugs used for non-seizure indications, angiotensin converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB) used for uncomplicated hypertension rather than for congestive heart failure, etc.) •• Note, as above, that antidiabetic drugs for any indication (except metformin) within 90 d of screening are excluded

ii. Vasodilating drugs for any indication: hydralazine, nitrates, phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil), minoxidil (oral)

iii. Phenytoin or fosphenytoin for any indication

iv. Oral or parenteral corticosteroids (at greater than prednisone 5 mg daily, or equivalent) for more than 3 days within the previous 90 days; topical and inhaled formulations are permitted

v. Fludrocortisone

vi. Opioids

10. History of certain weight-loss (bariatric) surgeries, including:

i. Roux-en-Y gastric bypass

ii. Biliopancreatic diversion

iii. Restrictive procedures (lap band, sleeve gastrectomy) performed within past 6 months

11. Clinical concern for alcohol overuse, including based on chart review and/or by participant's report of consuming more than 14 standard drinks per week for males or more than 7 standard drinks per week for females

12. Positive urine drug screen, except for:

• Lawfully prescribed medication
• Marijuana/THC positivity is okay, provided that the participant agrees not to use it during the same period that they will abstain from alcohol

13. History of severe infection or ongoing febrile illness within 30 days of screening

14. Any other disease or condition or laboratory value that, in the opinion of the investigator, would place the participant at an unacceptable risk and/or interfere with the analysis of study data.

15. Known allergy/hypersensitivity to any component of the medicinal product formulations (including sulfa drugs), other biologics, IV infusion equipment, plastics, adhesive or silicone, history of infusion site reactions with IV administration of other medicines, or ongoing clinically important allergy/hypersensitivity as judged by the investigator.

16. Concurrent enrollment in another clinical study of any investigational drug therapy or use of any biologicals within 6 months prior to screening or within 5 half-lives of an investigational agent or biologic, whichever is longer.

Exclusion Criteria

1. Unable to provide informed consent in English or Spanish

2. Concerns arising at screening visit (any of the following):

i. Documented weight loss of ≥ 5.0% of baseline within the previous 6 months

ii. Abnormal blood pressure (including on treatment, if prescribed) • Systolic blood pressure < 95 mm Hg or > 160 mm Hg, and/or

• Diastolic blood pressure < 65 mm Hg or > 100 mm Hg

iii. Abnormal resting heart rate < 60 bpm or ≥ 100 bpm

• Sinus brady- or tachycardia that has been appropriately evaluated and considered benign by the recruit's personal physician may be permitted at PI's discretion

iv. Abnormal screening electrocardiogram (or if on file, performed within previous 90 d):

• Non-sinus rhythm
• Significant corrected QT segment (QTc) prolongation (≥ 480 ms)
• New or previously unknown ischaemic changes that persist on repeat EKG:

•• ST segment elevations

•• T-wave inversions

v. Laboratory evidence of diabetes mellitus:

• Hemoglobin A1c ≥ 6.5%, and/or
• Fasting plasma glucose ≥ 126 mg/dL

vi. Positive qualitative serum β-hCG (human chorionic gonadotropin, beta subunit; i.e., pregnancy test) in women of childbearing potential

vii. Liver function abnormalities

• Transaminases (AST or ALT) > 3.0 x the upper limit of normal, and/or
• Total bilirubin > 1.25 x the upper limit of normal

viii. Abnormal screening triglycerides > 500 mg/dL

ix. Abnormal screening serum electrolytes (any of the following) • Sodium, potassium, chloride, or bicarbonate levels that are considered clinically significant according to the clinical judgment of the PI • Creatinine equating to estimated glomerular filtration rate < 60 mL/min/1.73 m2

x. Uric acid level above the upper limit of normal

xi. Glucose-6-phosphate dehydrogenase below the lower limit of normal

3. COVID-19 precautions

i. Unwillingness to comply with masking requirements per hospital policy

ii. Active, documented COVID-19 at any time after screening

4. Reproductive concerns

i. Women of childbearing potential not using highly effective contraception, defined as:

• Surgical sterilization (e.g., bilateral tubal occlusion, bilateral oophorectomy and/or salpingectomy, hysterectomy)
• Combined oral contraceptive pills taken daily, including during the study
• Intrauterine device (levonorgestrel-eluting or copper) active at the time of the study
• Medroxyprogesterone acetate (Depo-Provera®) injection active at the time of the study
• Etonogestrel implants (e.g., Implanon®, etc.) active at the time of the study
• Etonogestrel/ethinyl estradiol vaginal rings (e.g., Nuvaring®, etc.) active at the time of the study
• Norelgestromin/ethinyl estradiol transdermal system (e.g., Ortho-Evra®) active at the time of the study

ii. Women currently pregnant (tested by serum and/or urine β-hCG)

iii. Women currently breastfeeding

5. Concerns related to glucose metabolism

i. History of having met any of the American Diabetes Association's definitions of diabetes mellitus (i.e., overt diabetes):

• Hemoglobin A1c ≥ 6.5%, or rapid rise in documented HbA1c values causing clinical concern for evolving insulin deficiency
• Plasma glucose ≥ 126 mg/dL after 8-h fast
• Plasma glucose of ≥ 200 mg/dL at 2 h after ingestion of a 75-g glucose load
• Random plasma glucose ≥ 200 mg/dL associated with typical hyperglycemic symptoms, diabetic ketoacidosis, or hyperglycemic-hyperosmolar state

ii. History of gestational diabetes mellitus within the previous 5 years

iii. Use of most antidiabetic medications within the 90 days prior to screening

• Excluded: thiazolidinediones, sulfonylureas, meglitinides, dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, sodium-glucose cotransporter 2 (SGLT2) inhibitors, amylin mimetics, acarbose, insulin

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of California, Berkeley

OTHER

Sponsor Role: collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

Sponsor Role: collaborator

Columbia University

OTHER

Sponsor Role: lead

Responsible Party

Joshua Cook

Assistant Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Joshua R Cook, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Columbia University

Locations

Columbia University Irving Medical Center

New York, New York, United States

Countries

United States

Other Identifiers

K12DK133995

Identifier Type: NIH

Identifier Source: secondary_id

View Link

AAAU2570

Identifier Type: -

Identifier Source: org_study_id